Carregant...
Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
The treatment of metastatic renal cell carcinoma (mRCC) is rapidly changing. During first-line treatment with targeted therapy, patients ultimately develop resistance to therapy and the disease progresses. Recently, cabozantinib has demonstrated a better response rate, progression-free survival and...
Guardat en:
| Publicat a: | Ther Adv Urol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5117166/ https://ncbi.nlm.nih.gov/pubmed/27904650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287216663073 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|